David Epstein, Evelo chairman (Flagship Pioneering)
December 9, 2020 10:56 AM ESTUpdated 02:17 PM
R&D

Lit­tle Evelo sees big promise in its first cut of da­ta from a tiny study on atopic der­mati­tis

John Carroll

Editor & Founder

Any­one putting to­geth­er an ear­ly-stage tri­al in­volv­ing 24 pa­tients with a big-mar­ket dis­ease like atopic der­mati­tis wants to know one thing: Do they have a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times